Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beni-Suef Univ. STAT-3/c-Src compound 7c: sourced facts only. name: "Surprisingly, both derivatives 7c and 12d demonstrated more potent inhibitory activity (IC50 = 1.291 ± 0.055 and 0.844 ± 0.036 μM, sequentially) towards STAT-3 enzyme compared to the reference drug STAT3-IN-3 (IC50 = 2.1 ± 0.20 μM)."; target: "Surprisingly, both derivatives 7c and 12d demonstrated more potent inhibitory activity (IC50 = 1.291 ± 0.055 and 0.844 ± 0.036 μM, sequentially) towards STAT-3 enzyme compared to the reference drug STAT3-IN-3 (IC50 = 2.1 ± 0.20 μM)."; target: "Also, the pyrazoloquinazoline derivative 12d (IC50 = 0.268 ± 0.011 μM) showed highest inhibitory activity than the hydroxyimino derivative 7c (IC50 = 0.565 ± 0.024 μM) against c-Src enzyme compared to staurosporin (IC50 = 0.139 ± 0.006 μM) as reference drug."; developer: "Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt."
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beni-Suef Univ. STAT-3/c-Src compound 7c.
Work on Beni-Suef Univ. STAT-3/c-Src compound 7c? Claim this page to correct or add information. Claim this page